It's important to note that ritonavir, as a strong CYP3A4 inhibitor, may affect the metabolism of various drugs used for arrhythmia, diabetes, and neurological diseases, even when nirmatrelvir/ritonavir is used for a short duration (Loos et al., 2022). Here, CYP3A4 is linked to cardiac arrhythmia.